Cha Vaccine Institute
June 16, 2025
Company Presentation
Immunology
CHA Vaccine Institute (KOSDAQ: 261780) – Pioneering Next-Generation Vaccines & Immunotherapies
CHA Vaccine Institute is a cutting-edge biotechnology company dedicated to developing transformative therapeutic and prophylactic vaccines, as well as innovative cancer immunotherapies.
🔹 Proprietary Adjuvant Platforms: Our TLR2/TLR3 agonist combination significantly enhances vaccine efficacy and anti-cancer immune responses.
🔹 Addressing Critical Medical Needs: Targeting high-value markets, including Chronic Hepatitis B ($5.6B) and Herpes Zoster ($5.0B).
🔹Robust Clinical Pipeline: Advancing three clinical trials, including a Phase 2b vaccine and two Phase 1 prophylactic vaccines.
🔹 Strong Intellectual Property Portfolio: Protecting innovation with 40 global patents.
🔹 Expert Leadership: Led by a team of seasoned biotech professionals driving innovation and growth.
Company HQ City:
Seongnam-si, Gyeonggi-do
Company HQ State:
Korea, Republic of
Company HQ Country:
Korea, Republic of
Year Founded:
Jun. 2000 (acquired in 2011)
Lead Product in Development:
1. Novel Vaccine Adjuvant (L-pampo, Lipo-Pam):
HBV, Herpes Zoster Virus, Cancer therapeutic vaccines & more
2. Recombinant Antigen development:
3rd generation HBV antigen L-HBsAg (S+preS), HBcAg, VZV gE antigen, Cancer antigen CT45 etc
CEO
Jung Sun Yum (founder Dr. Hong Mo Moon)
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Best-in-Class Prophylactic Vaccine for Herpes Zoster:
- Improved safety, side effect profile
- Broader age group targeting
- Compatibility with conventional treatments
Exchange
Korean Won
Ticker
261780.KQ
When you expect your next catalyst update?
We expect to receive CVI-VZV-001 (Herpes Zoster) Phase 1 clinical report.
What is your next catalyst (value inflection) update?
June, 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}